PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Over the past decade, breakthroughs in understanding chronic rhinosinusitis with nasal polyps (CRSwNP) have revealed its complexity and the pivotal role of airway epithelial cells in driving inflammation. Alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, released upon epithelial injury, trigger and amplify both type 1 and type 2 inflammatory responses. Unlike existing biologics that target downstream type 2 pathways, innovative anti-alarmin therapies act upstream, offering promise for patients across inflammatory profiles. As these therapies near approval, clinicians must stay informed to navigate this evolving treatment landscape. Join us for an engaging, expert-led program exploring the science behind alarmins, emerging clinical trial data, and practical guidance on integrating these groundbreaking therapies into practice.

A New Target in Sight: Alarmin Cytokines and the Evolving Biologic Landscape in CRSwNP - Wednesday, March 25, 2026